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ABSTRACT 
To our knowledge, in spite of several trials exploring the beneficial effect of n-3 polyunsaturated fatty acids 
(PUFA) on polycystic ovary syndrome (PCOS), no comprehensive evidence has investigated the effects of n-3 
PUFA consumption on PCOS complications. Therefore, our aim was to conduct a review to investigate the pos-
sible effect and related mechanisms. A comprehensive systematic search was conducted in Embase, MED-
LINE/PubMed, Google Scholar, and SCOPUS, to identify studies investigating n-3 fatty acids as a preventative 
or therapeutic agent for the attenuation of PCOS complications. Subsequently, the impact of omega-3 on PCOS, 
omega-3 and inflammation, omega-3 and insulin resistance, omega-3 and adipokines, omega-3 and lipid metabo-
lism, omega-3 and endothelial function and omega-3 and hormonal factors were discussed. There are multiple 
mechanisms by which n-3 PUFAs may exert their beneficial effects on PCOS, including anti-obesity, glycemic 
and hormonal hemostasis, anti-inflammatory, regulation of adipokine production and enhancement of endotheli-
al function. N-3 PUFAs are a promising agent in relieving complications associated with PCOS. Although most 
of the studies in patients with PCOS reported an improvement in most complications after administration of 
omega-3 supplements, there is a distinct dearth of studies investigating the dietary intake of these types of fatty 
acids.  Moreover, favorable effects regarding the improvement of dyslipidemia, regulation of adipokines, regula-
tion of hormonal factors and enhancement of endothelial function are limited. Therefore, more trials are warrant-
ed to investigate palatable mechanisms for clarifying the metabolic and hormonal effects of these agents in 
PCOS.  
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INTRODUCTION 
Polycystic ovary syndrome (PCOS) is 
considered one of the most common female 
endocrine disorders with an approximate 
prevalence of 5–10 % (Rondanelli et al., 
2014; Dunaif, 1997; Asuncion et al., 2000), 
with sufferers at an increased risk of repro-
ductive-related disorders (Rondanelli et al., 
2014; Goodarzi et al., 2011). There are sev-
eral characteristics manifest in this syndrome 
including polycystic ovaries, irregular men-
struation, hyperandrogenism and obesity and 
its associated consequences, such as insulin 
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resistance, which is reported in about 5 to 20 
percent of women, depending upon the ap-
plied diagnostic criteria (Faghfoori et al., 
2017; Pourghassem Gargari et al., 2015). 
According to the Rotterdam ESHRE/ASRM 
sponsored PCOS consensus workshop, a 
positive diagnosis is considered when any 
two of the following three features are ob-
served; oligo-ovulation/anovulation, poly-
cystic ovaries on ultrasound examination 
and/or clinical and/or biochemical signs of 
hyperandrogenism (Rondanelli et al., 2014; 
Rotterdam ESHRE/ASRM-sponsored PCOS 
consensus workshop group, 2004). Addition-
ally, there are several endocrine abnormali-
ties in PCOS which result in metabolic alter-
ations, such as; insulin resistance (IR), hy-
perinsulinemia, central obesity and metabol-
ic syndrome (MeTS) (Rondanelli et al., 
2014), and their associated consequences, 
including increased risk of hypertension, de-
veloping type 2 diabetes (T2DM), 
dyslipidemia, cardiovascular disorders and 
atherosclerosis (Rondanelli et al., 2014; 
Solomon, 1999). The reasons for the mani-
festation of PCOS is not well established; 
despite this, a combination of parameters, in-
cluding genetic and/or epigenetic, environ-
mental factors and exposure to high levels of 
androgen prenatally are considered to, puta-
tively, play a role in the onset of the disor-
der. Previous studies have revealed environ-
mental factors may represent fundamental 
factors in the incidence and treatment of the 
disorder. Among these environmental fac-
tors, dietary patterns are considered as one of 
the most important and controllable factors 
(Faghfoori et al., 2017; Nardo et al., 2008; 
Dumesic et al., 2007; Xita and Tsatsoulis, 
2006). 
Although optimal treatment for PCOS is 
not yet fully determined; multifactorial ap-
proaches are advisable, including a combina-
tion of one or more of the most effective in-
terventional strategies, such as diet and life-
style changes, or the use of pharmaceuticals 
(hormonal agents: oral contraceptives/cyclic 
progestins, gonadotropins, antiestrogens, and 
metabolic agents such as insulin sensitizers). 
It has been shown in a recent survey of 138 
endocrinologists and 172 gynecologists, per-
formed by Cussons et al. (2005) and Liepa et 
al. (2008), that the majority of experts be-
lieve diet and exercise is the first step in the 
treatment of PCOS (Liepa et al., 2008). For 
instance, dietary fat, such as essential poly-
unsaturated fatty acids (PUFA) including 
omega-3 and omega-6 fatty acid, has been 
studied in relation to PCOS (Liepa et al., 
2008). Dietary sources of n-3 PUFA are lim-
ited in comparison with n-6 PUFA sources. 
Αlpha-linolenic acid (ALA) is synthesized 
by plants and is abundant in sources such as 
flaxseed and nuts or leaf (Geetha and 
Chakravarthula, 2018), whilst fish are con-
sidered among the richest sources of n-3 
PUFA eicosapentaenoic acid (EPA) and do-
cosahexaenoic acid (DHA) (Albracht-
Schulte et al., 2018; Ratnayake and Galli, 
2009; Jafarnejad and Sadegh, 2011; Li et al., 
2018). Omega-3 PUFAs are asserted to exert 
their favorable effects via the modulation of 
the amount and type of eicosanoids and by 
the regulation of both intracellular signaling 
pathways and transcription factor activities 
(Gray et al., 2013; Serhan et al., 2004; 
Babcock et al., 2003). Gene expression is 
another example of the possible mechanism 
of n-3 PUFA consumption in positively af-
fecting health indices (Gray et al., 2013; Ren 
et al., 1997). It seems that each of the afore-
mentioned mechanisms, or indeed a combi-
nation of them, contributes to the regulation 
of different aspects of PCOS, including in-
flammation, blood pressure regulation, plate-
let adhesion and heart rhythm (Gray et al., 
2013; Harris et al., 2008). 
It has been shown in previous trials that 
consumption of unsaturated fat-rich foods 
may decrease the risk of chronic diseases; 
which is particularly true regarding risk fac-
tors for metabolic disorders seen in PCOS 
patients, including dyslipidemia, impaired 
endothelial function, and insulin resistance 
(Faghfoori et al., 2017; Zivkovic et al., 
2007). To our knowledge, in spite of several 
trials exploring the beneficial effects of n-3 
PUFA on PCOS (Table 1), no comprehen-
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sive review regarding the effects of n-3 
PUFA consumption on PCOS complications 
has taken place. Therefore, our aim was to 
conduct a review to investigate the possible 
effect and related mechanisms of n-3 PUFA 
consumption on PCOS complications. 
 
 
 
Table 1: Characteristics of trials investigating effects of n-3 PUFAs on PCOS complications 
Study  
name Year 
Sample 
size 
Follow-
up  
duration 
(month) 
Intervention 
dosage Significant outcome 
Oner 2013 45 6 1,500 mg of omega-3 BMI, insulin and HOMA levels decreased 
significantly during treatment, but glucose 
levels did not change. In the hormonal 
profile, serum LH and testosterone levels 
decreased and sex hormone-binding 
globulin levels increased significantly. 
Khani 2017 87 6 2 g/day (two cap-
sules) omega‑3 sup-
plements 
Waist circumference (WC) was significant-
ly lower in omega-3 as compared to con-
trol. 
Rafraf 2012 61 2 four 1-g omega-3 fatty 
acids capsules/d 
(1,200 mg n-3) 
No significant effects on weight, BMI, 
waist circumference, and waist to hip ratio 
at the end of the study. Changes in serum 
visfatin levels were not significant in either 
of the groups. 
McEwen 2017 88 6 2 capsules of omega-
3/d (total equivalent to 
360 mg EPA and 240 
mg DHA/day) 
Waist circumference was significantly 
lower in the omega-3 group as compared 
to control. The measurements of weight 
and hip circumference did not change. 
Nomura 2018 72 12 pitavastatin with either 
sarpogrelate (PS) or 
EPA (PE) 
BMI decreased significantly. 
Amini 2018 60 3 2×1,000 mg/day fish 
oil omega-3 fatty acid 
The quantitative insulin sensitivity check 
index increased but serum insulin levels 
and HOMA-IR significantly decreased. 
Mirmasoumi 2018 60 3 1,000 mg flaxseed oil 
omega-3 fatty acids 
Insulin values and homeostasis model of 
assessment-estimated insulin resistance 
decreased but quantitative insulin sensitiv-
ity check index and hs-CRP significantly 
decreased compared to the placebo. 
Ebrahimi 2017 68 3 1,000 mg omega-3 
fatty acids from flax-
seed oil containing 
400 mg α-linolenic ac-
id plus 400 IU vitamin 
E supplements 
A significant decrease in insulin, homeo-
stasis model of assessment-estimated in-
sulin resistance, a significant increase in 
quantitative insulin sensitivity check index 
and any significant effect on fasting plas-
ma glucose and also significant reductions 
in serum total testosterone and free tes-
tosterone was observed. 
Jamilian 2018 60 3 50,000 IU vitamin D 
every 2 weeks plus 
2000 mg/day omega-
3 fatty acid from fish 
oil 
Serum hs-CRP significantly decreased, 
gene expression of IL-1 significantly 
downregulated, a significant effect on 
gene expression of IL-8, TNF-α and TGF-
β occured. Serum total testosterone levels 
decreased, but other hormonal measures 
didn't change. 
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Table 1 (cont.): Characteristics of trials investigating effects of n-3 PUFAs on PCOS complications 
Study  
name Year 
Sample 
size 
Follow-
up  
duration
(month) 
Intervention  
dosage Significant outcome 
Rahmani 2017 68 3 1,000 mg omega-3 
fatty acids from flax-
seed oil containing 
400 mg α-linolenic 
acid plus 400 IU vit-
amin E supplements 
omega-3 fatty acids 
Gene expression of PPAR-γ upregulat-
ed, gene expression of IL-1 and IL-8 
downregulated, but any significant effect 
on TNF-α and TGF-β wasn’t observed. 
Talari 2018 60 3 1,000 mg omega-3 
from flaxseed oil con-
taining 400 mg α-
linolenic acid plus 
400 IU vitamin E 
supplements 
Change in hs-CRP was significantly dif-
ferent between the intervention and pla-
cebo group. Significant decreases in 
maximum levels of left CIMT, mean left 
CIMT levels, maximum levels of right 
CIMT and mean right CIMT levels and 
also any significant effect on NO values 
between the two groups was observed. 
Mohammadi 2012 64 2 4 omega−3 fatty ac-
ids capsules (each 
one contained 180 
mg EPA and 120 mg 
DHA) 
Levels of adiponectin and  HDL-C  in-
creased but TC, LDL-C and TG  de-
creased. 
Mejia-
Montilla 
2018 195 3 omega-3 fatty acids Mean of adiponectin levels showed a 
statistically significant increase after 
treatment. 
Nadjarzadeh 2015 84 2 3 capsules of omega-
3 (each one con-
tained 180 mg EPA 
and 120 mg DHA) 
daily 
Visfatin concentration did not change in 
neither groups, but the mean of adi-
ponectin concentration increased in 
omega-3 group. 
Cussons 2009 25 2 4 g/d of omega-3 fat-
ty acids 
The mean of LH decreased about 1.74 
mlU/ml in omega-3 group. The mean of 
change of LH/FSH ratio between groups 
was significant and after the intervention, 
prolactin and FSH  did not meaningfully 
change in both groups. 
Phelan 2011 22 6 
(weeks) 
LC n-3 PUFA sup-
plement 
Fasting and postprandial plasma triacyl-
glycerol, apoB48, total cholesterol, HDL-
C, and LDL-C concentrations did not 
change. 
Kalgaonkar 2011 31 6 
(weeks) 
walnuts or almonds 
containing 31 g of to-
tal fat per day 
Walnuts increased sex hormone-binding 
globulin and almonds reduced free an-
drogen index 
 
 
 
IMPACT OF OMEGA-3 ON PCOS 
COMPLICATIONS: 
Omega-3 and obesity 
Overweight and obesity are observed in 
40 %–50 % of patients with PCOS and is 
considered a major risk factor for PCOS 
(Liepa et al., 2008; Carmina and Lobo, 
1999). The accumulation of excess weight 
can lead to adipose tissue dysfunction, a 
phenomenon that is mechanistically connect-
ed to the pathogenesis of MetS and compli-
cations such as insulin resistance in liver and 
skeletal muscle (Albracht-Schulte et al., 
2018; Kim and Moustaid-Moussa, 2000). It 
is assumed that lower serum n-3 PUFA con-
centrations (Albracht-Schulte et al., 2018; 
Karlsson et al., 2006), particularly DHA (in-
crease of n-6:n-3 ratio) (Albracht-Schulte et 
al., 2018; Karlsson et al., 2006), are associat-
ed with obesity, elevated waist circumfer-
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ence (Albracht-Schulte et al., 2018; Micallef 
et al., 2009) in adolescents (Karlsson et al., 
2006; Albracht-Schulte et al., 2018), and 
adults with obesity (Albracht-Schulte et al., 
2018; Micallef et al., 2009). Adipose tissue 
is considered an active endocrine organ 
which has the ability to secrete several adi-
pokines and hormones, such as leptin and ad-
iponectin, and cytokines, such as interleukin-
6 (IL-6) (Albracht-Schulte et al., 2018; 
Kalupahana et al., 2012). 
One of the primary treatments in manag-
ing obesity and its comorbidities is lifestyle 
modification with the aim of significant 
weight loss (Albracht-Schulte et al., 2018). 
Natural bioactive compounds, such as n-3 
PUFA, possess few side effects and could be 
considered a safe approach in comparison to 
other modalities of treatment (Albracht-
Schulte et al., 2018). There are a variety of 
putative mechanisms by which n-3 PUFA, 
particularly EPA and DHA, could work in 
improving body composition, modulating 
energy metabolism and reducing body 
weight (Albracht-Schulte et al., 2018). 
Adipocyte differentiation, which is con-
sidered a complex process in making adipose 
tissue, is mainly regulated by two different 
families of transcription factors, including 
peroxisome proliferator-activated receptor γ 
(PPAR-γ) and CCAAT/enhancer-binding 
proteins (C/EBPs) (Martinez-Fernandez et 
al., 2015). It has been shown that DHA, in 
dosages of ≥ 50 μM, could facilitate the dif-
ferentiation of adipocytes by up-regulation 
of mRNA levels of adipocyte protein 2 (aP2) 
and C/EBPα, PPARγ in 3T3-L1 cell lines 
(Martinez-Fernandez et al., 2015; Murali et 
al., 2014). Furthermore, accumulation of li-
pid droplets results in increased levels of 
PPARγ following administration of EPA 
(250 μM) (Martinez-Fernandez et al., 2015; 
Hanada et al., 2011). Additionally, previous 
studies have highlighted that n-3 PUFAs can 
modulate the apoptosis of adipocytes 
(Martinez-Fernandez et al., 2015; Kim et al., 
2006). Collectively, it seems that marine-
origin n-3 PUFAs may have the potential to 
regulate the adipocyte number and size via 
modulating adipocyte differentiation and 
apoptosis (Martinez-Fernandez et al., 2015). 
Indeed, several studies have reported favora-
ble outcomes of omega-3 consumption on 
obesity. For instance, in Oner and Muderris 
(2013), BMI decreased significantly with 
daily oral administration of 1,500 mg ome-
ga-3 for 6 months (Oner and Muderris, 
2013). In another trial, which was conducted 
in PCOS patients, the subjects consumed 
omega-3 in doses of 2 g/day for 6 months, 
after which, waist circumference (WC) was 
significantly lower in those that consumed 
omega-3 vs. the control group (Khani et al., 
2017). Similar outcomes were reported in 
McEwen (2017), where participants received 
2 capsules of omega-3 PUFA acids per day, 
and at the end of the trial, WC was signifi-
cantly lower in the omega-3 group vs. the 
control group (McEwen, 2017). The findings 
of combination therapy have also shown 
promising effects, for instance, BMI de-
creased significantly following administra-
tion of pitavastatin and, either, EPA 1,800 
mg or sarpogrelate 300 mg for 12 months in 
diabetic patients with arteriosclerosis 
(Nomura et al., 2018). Conversely, it has 
been reported that consuming 4 g of omega-
3 PUFA capsules, per day, for 8 weeks did 
not elicit any significant effect on weight, 
BMI, waist circumference, or waist to hip ra-
tio (Rafraf et al., 2012). However, the con-
tradictory results are limited, and most pre-
vious studies have reported favorable effects 
of n-3 PUFA supplementation on obesity. 
 
Omega-3 and insulin resistance 
Insulin resistance is defined as a condi-
tion in which the response of peripheral tis-
sue to insulin is reduced (Lepretti et al., 
2018). This disorder occurs mostly in the 
skeletal muscle and the liver, with several 
negative impacts on glucose metabolism, 
which is mostly attributed to the defective 
regulation of glucose transporter isoform 4 
(GLUT4). It seems that the skeletal muscle 
may play a substantial role in insulin re-
sistance (Lepretti et al., 2018; DeFronzo and 
Tripathy, 2009; Lark et al., 2012). Impaired 
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suppression of gluconeogenesis, glycogenol-
ysis in the liver, and suppression of glucose 
output are among the complications associ-
ated with insulin resistance (Home and 
Pacini, 2008; Boden, 2011; Lepretti et al., 
2018). The impaired suppression of lipolysis 
observed in white adipose tissue (WAT) con-
tributes to hyperlipidemia in insulin-resistant 
subjects (Lepretti et al., 2018; Boden, 2011). 
Brown adipose tissue (BAT) also plays an 
essential role in glucose metabolism 
(Lepretti et al., 2018; Stanford et al., 2013), 
where it is demonstrated that the whole-body 
energy homeostasis can be regulated by 
BAT, with the dissipation of chemical ener-
gy as heat via mitochondrial uncoupling pro-
tein 1 (UCP1). 
Insulin resistance has been reported in 
30 % of lean and 75 % of obese patients with 
PCOS, whilst the severity of insulin re-
sistance is more than would be expected for 
a given age and body weight (O'Connor et 
al., 2010; Jonard and Dewailly, 2004). The 
observed fasting hyperinsulinemia in obese 
PCOS patients is secondary to increased ba-
sal insulin secretion rates (Dunaif, 1997; 
O'Meara et al., 1993). Obesity results in in-
sulin resistance, which is accountable for the 
pathogenesis of MetS (Albracht-Schulte et 
al., 2018; Kim and Moustaid-Moussa, 2000). 
Previous studies have demonstrated an im-
provement in insulin resistance after weight 
loss interventions) (Albracht-Schulte et al., 
2018; Kim and Moustaid-Moussa, 2000) and 
several studies recommend that insulin re-
sistance leads to significant disturbances in 
both metabolic and reproductive homeosta-
sis, and thus may possess an essential role in 
the pathogenesis of PCOS (Gunalan et al., 
2018; Diamanti-Kandarakis and Dunaif, 
2012). In brief, insulin may exert its role in 
hyperandrogenism in PCOS pathophysiology 
via two distinct pathways: 1) stimulation of 
androgen production of theca cells with lute-
inizing hormone (LH) and increased andro-
gen production which results in hirsutism 
and infertility. 2) Suppression of sex hor-
mone-binding globulin (SHBG) synthesis in 
the liver (Gunalan et al., 2018; Ehrmann, 
2005). SHBG is considered to be a plasma 
protein for androgen and estrogens; there-
fore, any decrement in SHBG levels could 
result in hyperandrogenism in PCOS suffer-
ers. Metabolically, insulin plays an integral 
role in regulating glucose homeostasis, the 
activation of amino acid transportation, and 
suppression of lipolysis (Gunalan et al., 
2018; Kahn, 1994). Mechanistically, it has 
been suggested that omega-3 PUFA may 
have beneficial effects on insulin sensitivity 
by attenuating endoplasmic reticulum (ER) 
stress, and increasing β-oxidation of mito-
chondrial fatty acid and mitochondrial un-
coupling, with a concomitant reduction in li-
pid deposits and reactive oxygen species 
(ROS) production. Consequently, inflamma-
tory processes are down-regulated, thereby 
enhancing insulin sensitivity. Another puta-
tive mechanism is related to mitochondrial 
fusion proteins - mitofusins 2 (Mfn2), which 
is involved in the maintenance of mitochon-
drial dynamics homeostasis and integrity of 
mitochondria-associated endoplasmic reticu-
lum membrane (MAM). In the case of cellu-
lar stress, MAM integrity and mitochondrial 
fusion phenotype may facilitate maintenance 
of insulin sensitivity (Lepretti et al., 2018). 
There are some studies that show the ef-
fect of omega-3 supplementation on insulin 
resistance. In the study of Oner and Muderris 
(2013) insulin levels significantly decreased 
following 6 months of omega-3 consump-
tion; whereas there were no reported signifi-
cant changes in glucose levels and HOMA 
index. In another trial, 30 participants con-
sumed 2 g/day fish oil omega-3 fatty acid for 
12 weeks; following which, a significant in-
crease in the quantitative insulin sensitivity 
check index, serum insulin levels, and 
HOMA-IR were reported, respectively 
(Amini et al., 2018). Mirmasoumi et al. re-
ported a decrease in insulin values and ho-
meostasis model of assessment-estimated in-
sulin resistance, and an increase in quantita-
tive insulin sensitivity check index after ad-
ministrating 1 g/day flaxseed oil omega-3 
fatty acids for 12 weeks (Mirmasoumi et al., 
2018). Similarly, a significant decrease in in-
EXCLI Journal 2019;18:558-575 – ISSN 1611-2156 
Received: June 14, 2019, accepted: July 23, 2019, published: July 25, 2019 
 
 
564 
sulin, homeostasis model of assessment-
estimated insulin resistance and a significant 
increase in quantitative insulin sensitivity 
check index were observed after 12 weeks 
intervention of omega-3 fatty acids and vit-
amin E co-supplementation (Ebrahimi et al., 
2017). However, in a recent meta-analysis 
which investigated the effect of omega-3 
PUFA supplementation on insulin resistance 
in women with PCOS, no beneficial effect 
on insulin resistance and HOMA−IR was ob-
served in comparison to the placebo group 
(Sadeghi et al., 2017).  
 
Omega-3 and inflammation 
Chronic low-grade inflammation is nor-
mally involved in the pathogenesis of obesi-
ty-related disorders. Leukocytes in the adi-
pose-tissue and circulation can enhance the 
insulin resistance in type 2 diabetes and obe-
sity (Escobar-Morreale et al., 2011; 
Fernandez-Real and Ricart, 2003). Polycys-
tic ovary syndrome contributes to a pro-
inflammatory state (Escobar-Morreale et al., 
2011), and an association between molecular 
level inflammation and insulin resistance has 
been well reported (Escobar-Morreale et al., 
2011; González et al., 2006a, b). Moreover, 
there are elevations in several circulating 
pro-atherogenic inflammatory modulators in 
PCOS (Escobar-Morreale et al., 2011; 
Diamanti-Kandarakis et al., 2006a, b; 
Lewandowski et al., 2006; Hu et al., 2006), 
which are accompanied by glucose-
stimulated up-regulation of pro-atherogenic 
molecular pathways (Escobar-Morreale et 
al., 2011; González et al., 2006a). However, 
it remains unknown whether the pro-
inflammatory state and increase of circulat-
ing inflammatory mediators in PCOS are re-
lated to PCOS itself, or are primary manifes-
tations of the inflamed status of adipose tis-
sue (Escobar-Morreale et al., 2011; Carmina 
et al., 2007). 
N-3 PUFAs influence the production of 
several inflammatory markers, such as adhe-
sion molecules and cytokines (Calder, 2017), 
whilst the most focused markers are the clas-
sic pro-inflammatory cytokines, tumor ne-
crosis factor (TNF)-α, IL-6 and interleukin 
(IL)-1β. Many cell culture and animal re-
ports, respectively, have reported that 
EPA/DHA can reduce the formation of TNF-
α, IL-6, and IL-1β in response to lipopoly-
saccharide (LPS) exposure (Calder, 2017, 
2015). Whilst other studies have shown that 
EPA and DHA may lead to an increase in the 
cytokine IL-10 concentration, which is anti-
inflammatory (Calder, 2017, 2015). Addi-
tionally, it has been reported that n-3 
PUFAs, especially DHA, could decrease the 
expression of adhesion molecules, such as 
intercellular adhesion molecule (ICAM)-1 
and vascular cell adhesion molecule 
(VCAM)-1, on the surface of monocytes and 
endothelial cells (Calder, 2017, 2015). It 
seems that the alterations in the expression 
of genes responsible for encoding the cyto-
kines and inflammatory mediators induce the 
anti-inflammatory effects of n-3 PUFAs 
(Calder, 2017, 2015). This suggests that n-3 
PUFAs impact the signaling pathways, and, 
as a consequence, control gene expression in 
inflammatory cells. 
Another mechanism by which EPA and 
DHA might have an effect on nuclear factor 
kappa B (NF-κB) activation, and the ability 
to induce transcription of pro-inflammatory 
genes, is related to PPAR-γ. This is consid-
ered to be a transcription factor which acts in 
an anti-inflammatory manner, which is likely 
attributable to its interference with the trans-
location of NF-κB to the nucleus. It has been 
reported that n-3 PUFAs can induce the 
PPAR-γ (Calder, 2017; Forman et al., 1997; 
Krey et al., 1997) and DHA, specifically,  
can activate PPAR-γ in dendritic cells 
(Calder, 2017; Kong et al., 2010); which is 
accountable for inhibition of NF-κB activa-
tion and reduced production of the pro-
inflammatory cytokines, including TNF-α 
and IL-6 and LPS stimulation (Calder, 2017; 
Kong et al., 2010). Furthermore, PPAR-γ 
target genes in dendritic cells are induced by 
DHA (Calder, 2017; Zapata-Gonzalez et al., 
2008), suggesting that it may be a considera-
ble anti-inflammatory mechanism attributa-
ble to DHA. Similarly, EPA derivatives, 15-
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deoxy-PGD3 and PGD3, can induce PPAR-γ 
in adipocytes, which results in the activation 
of the anti-inflammatory adipokine adi-
ponectin production (Calder, 2017; Lefils-
Lacourtablaise et al., 2013). 
There are several reports suggesting that 
n-3 PUFA can improve inflammatory status 
in PCOS patients (Jamilian et al., 2018; 
Talari et al., 2018). In one study, co-
supplementation of 3 g/day omega-3 from 
fish oil, with 50000 IU vitamin D, signifi-
cantly decreased serum high-sensitivity C-
reactive protein (hs-CRP), and down-
regulated gene expression of IL-1; however, 
there was no significant effect on gene ex-
pression of IL-8, TNF-α or transforming 
growth factor beta (TGF-β) (Jamilian et al., 
2018). In another study, flaxseed oil omega-
3 fatty acid supplementation resulted in a 
significant decrease in hs-CRP (Mirmasoumi 
et al., 2018), whilst Rahmani et (2017) 
demonstrated that consumption of 1 g/day 
omega-3 fatty acids from fish oil, for 12-
weeks, resulted in up-regulation of PPAR-γ 
and down-regulation in gene expression of 
IL-1 and interleukin-8 (IL-8) (Rahmani et 
al., 2017). Evidently, most previous studies 
emphasize the efficacy of n-3 PUFA admin-
istration in relieving inflammatory status in 
PCOS patients.   
 
Omega-3 and adipokines 
The adipokine alteration is considered to 
be a specific complication of PCOS, yet it is 
not fully understood whether such dysregula-
tion is secondary to PCOS complications 
such as obesity, hyperinsulinemia, and hy-
perandrogenism, or directly related to PCOS 
(Baldani et al., 2019). Adiponectin and leptin 
are among the adipokines secreted from adi-
pocytes (Farimani et al., 2018; Das et al., 
2013), and it has been shown that different 
adipokines can promote both inflammatory 
and anti-inflammatory activities (Farimani et 
al., 2018; Nomura et al., 2009). It seems that 
adiponectin expression as an anti-
inflammatory adipokine is reduced in obese 
individuals, whilst expression of leptin as an 
inflammatory adipokine is elevated, com-
pared to the lean subjects (Farimani et al., 
2018; Kang et al., 2016; Ouchi et al., 2011). 
The higher leptin concentration in obese sub-
jects, which is due to leptin resistance, is re-
lated to higher concentrations of inflammato-
ry markers, including TNF-α and CRP. In 
addition to the inflammatory responses of 
adipokines, it has been suggested that adi-
ponectin and leptin can regulate appetite and 
energy expenditure, which results in an al-
teration of insulin sensitivity. (Farimani et 
al., 2018; Gray et al., 2013). N-3 PUFA’s de-
rived from plant and marine sources have 
been introduced as potential factors affecting 
the concentration of inflammatory and non-
inflammatory adipokines (Farimani et al., 
2018; von Frankenberg et al., 2014). Eleva-
tion of circulating adiponectin levels and re-
duced levels of leptin have been reported af-
ter n-3 PUFAs administration in previous 
studies (Farimani et al., 2018; von Franken-
berg et al., 2014; Hariri et al., 2015), which 
is associated with improved function of skel-
etal muscle mitochondria, and, consequently, 
increased glucose uptake. N-3 PUFA normal-
izes the secretory activity of adipocytes and 
improves adiponectin-mediated insulin sensi-
tivity in skeletal muscle and the liver (Fari-
mani et al., 2018). Moreover, this can stimu-
late the activation of 5′AMP-activated pro-
tein kinase (AMPK) and PPARγ, which reg-
ulate metabolism by increasing glucose con-
sumption and fatty acid oxidation in the liver 
and skeletal muscle (Farimani et al., 2018; 
Gray et al., 2013; Perez-Matute et al., 2007; 
Tomas et al., 2002; Yamauchi et al., 2003). 
However, it seems that the effect omega-3 
elicits on adipokine levels is equivocal, and 
widely dependent on several parameters, 
such as diet composition, the physiological 
and metabolic status of subjects (Farimani et 
al., 2018; Moreno-Aliaga et al., 2010).  
There are several studies related to the 
effect of omega-3 fatty acids on adipokine 
secretion, for instance, Mohammadi et al. re-
ported an increase of adiponectin by 19.5 % 
via inducing omega-3 fatty acids supplemen-
tation for 8 weeks (Mohammadi et al., 2012). 
In another study by Mejia-Montilla et al. 
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(2018), PCOS patients treated with omega-3 
fatty acids for 12 weeks significantly in-
creased mean levels of adiponectin. Similar-
ly, in a study conducted in PCOS sufferers, 
following omega-3 supplementation (3 caps/ 
day, each containing 180 mg EPA and 120 
mg DHA) for 8 weeks, mean adiponectin 
concentration increased in the omega-3 
group, whilst visfatin concentration re-
mained unchanged (Nadjarzadeh et al., 
2015). In Rafraf et al. (2012), patients with 
PCOS took 4 g omega-3 fatty acids capsules 
per day, providing 1200 mg n-3 long-chain 
polyunsaturated fatty acids (n-3 LC PUFA), 
for 8 weeks. The incumbent changes in se-
rum visfatin levels were not significant in ei-
ther the intervention or placebo groups 
(Rafraf et al., 2012). In summary, the studies 
investigating the effects of n-3 PUFA on ad-
ipokines, particularly in PCOS, are limited, 
and further studies are warranted to clarify 
the possible efficacy of, and mechanisms as-
sociated with, improving PCOS complica-
tions.   
 
Omega-3 and lipid metabolism 
Significant changes in the production of 
FFAs, phospholipids, and bioactive lipids 
have been observed in obese and lean wom-
en with PCOS. The reported dyslipidemia in 
the PCOS population is characterized by re-
duced high density lipoprotein (HDL) cho-
lesterol concentrations as the main outcome, 
and possible elevated levels of triacylglycer-
ol (TAG), very low density lipoprotein 
(VLDL) and/or atherogenic non-A low den-
sity lipoprotein (LDL) cholesterol pattern as 
the secondary outcome (O'Connor et al., 
2010; Westerveld et al., 2008).  
There are several studies that have re-
ported an inverse association between plas-
ma HDL-C levels and the incidence of CVD 
disorders (Pizzini et al., 2017; Rader, 2003; 
Kannel et al., 1964; Assmann et al., 2002), 
which emphasizes the potential atheroprotec-
tive effects of higher concentrations of HDL-
C (Pizzini et al., 2017; Siddiqi et al., 2015). 
The beneficial effect of HDL as a CVD pro-
tecting factor is mediated by the Reverse 
Cholesterol Transport (RCT) activity of 
HDL-C. This process explains the cholester-
ol clearing pathways of peripheral, subendo-
thelial macrophage, and fibroblast-derived 
cholesterol via direct (via hepatic uptake via 
scavenger receptor B-I (SR-BI)), and indirect 
(via shifting cholesterol from HDL particles 
to apoB-containing lipoproteins) pathways 
(Mahdy Ali et al., 2012; Siddiqi et al., 2015; 
Pizzini et al., 2017). Another potential 
mechanism by which n-3 PUFAs may exhib-
it their atheroprotective activities is through 
enhancement of intracellular catabolism of 
apolipoprotein B-100 lipoproteins and curb-
ing hepatic apo-B production. This leads to 
stimulation of lipoprotein lipase (LPL), and 
increases plasma triglyceride clearance, con-
version of the VLDL to LDL, and reducing 
the synthesis of LDL and reducing postpran-
dial lipemia (Pizzini et al., 2017; Chan et al., 
2002, 2003; Park and Harris, 2003; Robinson 
and Stone, 2006). It seems that n-3 PUFAs 
exert their effect by inhibiting sterol regula-
tory element-binding protein-1 (SREBP-1) 
mediated pathways, including the activation 
of Liver X Receptor (LXR), the nuclear tran-
scription factors, Farnesoid X Receptor, 
Hepatocyte Nuclear Factor-4 Alpha 
(HNF4A), and Peroxisome Proliferator-
activated Receptors (PPARs) (Pizzini et al., 
2017; Zuliani et al., 2009). Different types of 
n-3 PUFA may elicit different activities re-
garding lipid metabolism; unlike DPA and 
DHA, which are deposited in the tissues and 
spared from catabolism, EPA is mostly di-
rected towards β-oxidation (Albracht-Schulte 
et al., 2018; Ghasemifard et al., 2015). Addi-
tionally, it has been revealed that co-
supplementation with EPA/ DHA or single 
supplementation of DHA leads to a decrease 
in gene expression of fatty acid synthase, 
LPL, hormone-sensitive lipase (HSL), and 
phosphoenolpyruvate carboxykinase 
(PEPCK) in retroperitoneal fat; however, 
such effects were not evident in EPA sup-
plementation alone (Albracht-Schulte et al., 
2018; Raclot et al., 1997) . 
Although there are numerous reports of 
dyslipidemia in PCOS, studies investigating 
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the effects of n-3 PUFA on lipid metabolism 
in PCOS patients are limited. However, sev-
eral studies have reported an improvement in 
lipid regulation after n-3 PUFA supplemen-
tation in other metabolic disorders. In a study 
by Cussons et al. (2009) omega-3 fatty acids 
led to a decrease in hepatic fat in PCOS 
women with hepatic steatosis. In another 
study, omega-3 fatty acids supplementation, 
in PCOS patients, significantly increased 
HDL-C, and decreased TC, LDL-C and TG 
(Mohammadi et al., 2012); whilst in Rahma-
ni et al. (2017), 12 weeks co-
supplementation of omega-3 fatty acids and 
vitamin E resulted in a significant decrease 
in serum triglycerides, VLDL, total, LDL- 
and total-/HDL-cholesterol in PCOS patients 
(Rahmani et al., 2017). However, contrary to 
previous studies, Phelan et al. (2011) report-
ed no significant improvement in fasting and 
postprandial plasma triacylglycerol, apo-
B48, total cholesterol, HDL cholesterol, and 
LDL cholesterol concentrations in response 
to LC n-3 PUFA supplementation for 6 
weeks in PCOS sufferers (Phelan et al., 
2011). Notwithstanding, as only a limited 
number of trials have investigated n-3 PUFA 
supplementation as a conduit to improve 
PCOS complications, and that different types 
of n-3 PUFA may exert different activities 
and functions, more studies are warranted to 
clarify the mechanisms and effects of n-3 
PUFA on lipid metabolism in PCOS.   
 
Omega-3 and endothelial function 
In addition to dyslipidemia, endothelial 
dysfunction, which is defined as the reduc-
tion of vasodilatory and anti-inflammatory 
parameters and an increase in vasoconstric-
tive and pro-inflammatory parameters, is 
considered to be another significant indicator 
in women with PCOS which may lead to an 
increased risk for atherosclerotic cardiovas-
cular (CV) diseases (Wenner et al., 2011; 
Abbott et al., 2002). Evidence from previous 
studies has demonstrated that the cardiopro-
tective effects of n-3 PUFAs are manifest 
through improvements in vascular function. 
Several mechanisms, including decreased ar-
terial plaque build-up (Zehr and Walker, 
2018; Renier et al., 1993), increased anti-
inflammatory properties (Zehr and Walker, 
2018; Calder, 2006), enhanced endothelial-
dependent vasodilation as measured by flow-
mediated dilation (FMD) (Zehr and Walker, 
2018; Wiest et al., 2017; Goodfellow et al., 
2000; Siasos et al., 2013), lowering blood 
pressure (Zehr and Walker, 2018; Ulu et al., 
2014; Hoshi et al., 2013; Miller et al., 2014), 
elevated antioxidant capacity (Zehr and 
Walker, 2018; Thorlaksdottir et al., 2006) 
and production of nitric oxide (Albracht-
Schulte et al., 2018; Harris et al., 1997) have 
been suggested. In spite of the apparent dys-
function of endothelial function in PCOS 
women, there is a dearth of related studies 
investigating the potential beneficial effects 
of n-3 PUFA, except for Talari et al. (2018), 
who indicated a significant decrease in max-
imum levels of left carotid intima-media 
thickness (CIMT), mean left CIMT levels, 
maximum levels of right CIMT, and mean 
right CIMT levels after 12-week co-
supplementation with Omega-3 and vitamin 
E (Talari et al., 2018).  
 
Omega-3 and hormonal factors 
Hyperandrogenism is considered to be a 
basic characteristic of PCOS (Gunalan et al., 
2018; Stein et al., 2016), and is often associ-
ated with excessive release of luteinizing 
hormone (LH) by the pituitary gland and is 
related with hyperinsulinemia and insulin re-
sistance (Liepa et al., 2008; Ehrmann, 2005). 
The mechanisms by which insulin resistance 
impacts the hormonal system are numerous, 
moreover, it has been shown that insulin in-
duces elevated androgen production and 
produces a hormonal milieu which results in 
hirsutism. The improvement in the reproduc-
tive system has been attributed to an im-
provement in LH concentration and 
LH/Follicle stimulating hormone (FSH) ra-
tio, where the potential mechanistic action 
can be attributed to arachidonic acids 
(Nadjarzadeh et al., 2015; Phelan et al., 
2011). Arachidonic acid can activate a 
steroidogenic acute regulatory protein 
EXCLI Journal 2019;18:558-575 – ISSN 1611-2156 
Received: June 14, 2019, accepted: July 23, 2019, published: July 25, 2019 
 
 
568 
(StAR), which is considered to be the rate-
limiting tenet of the steroidogenic pathway. 
StAR transfers the cholesterol to the inner 
part of the mitochondrial membrane, which 
is considered the first and the most important 
step in the steroidogenic pathway and leads 
to the production of both androstenedione 
and testosterone. Therefore, high concentra-
tions of arachidonic acid can result in LH-
stimulated steroidogenesis, whilst current ev-
idence suggests that the reduced availability 
of arachidonic acid is related to levels of 
omega-3 (Nadjarzadeh et al., 2015; Phelan et 
al., 2011). 
Jamilian et al. (2018) reported that a de-
creased total serum level of testosterone was 
evident after co-supplementation of vitamin 
D and omega-3 fatty acid (50,000 IU vitamin 
D every 2 weeks plus 2000 mg/day omega-3 
fatty acid from fish oil) for 12 weeks, whilst 
in another study, supplementing with omega-
3 fatty acids from flaxseed oil plus vitamin E 
for 12 weeks in PCOS women, resulted in 
significant reductions in serum total testos-
terone and free testosterone (Ebrahimi et al., 
2017). A similar effect of omega-3 consump-
tion on hormonal factors in PCOS women 
was observed in Oner and Muderris (2013); 
where the participants were treated with 
1,500 mg of omega-3, daily, for 6 months. 
Resultantly, serum LH and testosterone lev-
els decreased and sex hormone-binding 
globulin levels increased significantly (Oner 
and Muderris, 2013). Contrastingly, in Nad-
jarzadeh et al. (2015), PCOS women sup-
plemented with 3 capsules of omega-3 (each 
one contained 180 mg EPA and 120 mg 
DHA) daily for 8 weeks, which resulted in 
no change in FSH. However, mean LH de-
creased by 1.74 mlU/ml in the omega-3 
group, and the mean change in LH/FSH ratio 
between groups was significant; moreover, 
the authors reported no meaningful change in 
prolactin levels (Nadjarzadeh et al., 2015). 
The aforementioned studies have predomi-
nantly explored the effect of n-3 PUFA sup-
plements, Kalgaonkar et al., however, fo-
cused on dietary intake. In Kalgaonkar et al. 
(2011), thirty-one PCOS patients consumed 
either walnuts or almonds containing 31 g of 
total fat per day for 6 weeks. Walnut con-
sumption increased sex hormone-binding 
globulin, whilst almond consumption re-
duced free androgen index (Kalgaonkar et 
al., 2011).  
 
CONCLUSIONS 
N-3 PUFAs are a promising agent in re-
lieving complications associated with PCOS. 
There are multiple mechanisms by which n-3 
PUFAs may exert their beneficial effects on 
PCOS women, including anti-obesity, gly-
cemic and hormonal homeostasis, anti-
inflammatory, regulation of adipokine pro-
duction and enhancement of endothelial 
function (Figure 1). Whilst studies investi-
gating the effect of omega-3 supplements in 
patients with PCOS have reported an im-
provement in numerous complications and 
comorbidities, including insulin resistance, 
dyslipidemia, hyperandrogenism, and regula-
tion of metabolic indicators; there is a dis-
tinct dearth of studies investigating the die-
tary intake of these types of fatty acids. 
Therefore, more studies are needed to inves-
tigate the effect of dietary fatty acids on 
PCOS complications. Moreover, there are, 
evidentially, numerous beneficial effects as-
sociated with n-3 PUFA consumption on 
PCOS complications, however, favorable ef-
fects regarding the improvement of 
dyslipidemia, regulation of adipokines and 
regulation of hormonal factors and endothe-
lial function are limited. Therefore, given the 
importance of these complications in the 
pathogenesis of PCOS, more trials are war-
ranted to investigate mechanisms to clarify 
the metabolic and hormonal effects of these 
agents in PCOS women. Additionally, to our 
knowledge, the use of n-3 PUFA on infertile 
PCOS patients has not been investigated in 
previous studies, and more studies are neces-
sary to assess the role of n-3 PUFA in the 
treatment of PCOS induced infertility. 
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Figure 1: Possible mechanisms describing the effects of n-3 PUFAs on PCOS complications. PPARγ, 
peroxisome proliferator-activated receptor γ; ER, endoplasmic reticulum; ROS, reactive oxygen spe-
cies; Mfn2, mitochondrial fusion proteins—mitofusins 2; IL-, interleukin; TNF-α, tumour necrosis factor; 
VCAM-1, vascular cell adhesion molecule; ICAM-1, intercellular adhesion molecule; NF-κB, nuclear 
factor kappa B; hs-CRP, high-sensitivity C-reactive protein; LPL, lipoprotein lipase; VLDL, very low 
density lipoprotein; LDL, low density lipoprotein; HSL, hormone-sensitive lipase; PEPCK, phosphoe-
nolpyruvate carboxykinase; SREBP-1, sterol regulatory element-binding protein-1; FMD, flow-
mediated dilation; NO, nitric oxide; LH, luteinizing hormone; FSH, follicle stimulating hormone; StAR, 
steroidogenic acute regulatory protein; SHBG, sex hormone-binding globulin 
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